



NDA 21-024/S-017
NDA 21-024/S-018

SUPPLEMENT APPROVAL

Sanofi US Services Inc.
On behalf of sanofi-aventis US, LLC
Attention: Praveena Deenumsetti
Manager, Global Regulatory Affairs
55 Corporate Drive
Bridgewater, NJ 08807

Dear Ms. Deenumsetti:

Please refer to your supplemental new drug applications (sNDAs) dated and received June 5, 2019 (S-017) and June 26, 2019 (S-018), and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Priftin (rifapentine) tablets.

These Prior Approval supplemental new drug applications provide for the following updates to the labeling:

Supplement S-017:

The **HIGHLIGHTS, WARNINGS AND PRECAUTIONS (5), ADVERSE REACTIONS (6), PATIENT COUNSELING INFORMATION (17)** sections and the **MEDICATION GUIDE**.

Supplement S-018:

The **USE IN SPECIFIC POPULATIONS (8)** section to comply with the FDA published requirements for the Pregnancy and Lactation Labeling Rule as well as minor editorial changes.

APPROVAL & LABELING

We have completed our review of these applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling text for the Prescribing Information and Medication Guide, with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Carmen DeBellas, PharmD, RPh, Chief Regulatory Project Manager, at 301-796-1203.

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

NDA 21-024/S-017

NDA 21-024/S-018

Page 3

Sincerely,

{See appended electronic signature page}

Dmitri Iarkov, MD, PhD
Deputy Director
Division of Anti-Infectives
Office of Infectious Diseases
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information
 - Medication Guide

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

DMITRI IARIKOV
06/05/2020 03:25:50 PM